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Abstract
The hepato-intestinal induction of the detoxifying enzymes CYP3A4 and CYP3A5 by the xenosensing pregnane X receptor
(PXR) constitutes a key adaptive response to oral drugs and dietary xenobiotics. In contrast to CYP3A4, CYP3A5 is
additionally expressed in several, mostly steroidogenic organs, which creates potential for induction-driven disturbances of
the steroid homeostasis. Using cell lines and mice transgenic for a CYP3A5 promoter we demonstrate that the CYP3A5
expression in these organs is non-inducible and independent from PXR. Instead, it is enabled by the loss of a suppressing
yin yang 1 (YY1)-binding site from the CYP3A5 promoter which occurred in haplorrhine primates. This YY1 site is conserved
in CYP3A4, but its inhibitory effect can be offset by PXR acting on response elements such as XREM. Taken together, the loss
of YY1 binding site from promoters of the CYP3A5 gene lineage during primate evolution may have enabled the utilization
of CYP3A5 both in the adaptive hepato-intestinal response to xenobiotics and as a constitutively expressed gene in other
organs. Our results thus constitute a first description of uncoupling induction from constitutive expression for a major
detoxifying enzyme. They also suggest an explanation for the considerable tissue expression differences between CYP3A5
and CYP3A4.
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Introduction
Transcriptional activation of metabolizing enzymes and trans-
porters in the small intestine and in the liver constitutes the most
important adaptive response to oral drugs and dietary xenobiotics.
The involved transcription factors are activated by xenobiotics and
are therefore collectively referred to as xenosensors. Due to its
wide ligand-binding spectrum, the pregnane X receptor (PXR,
NR1I2) is the most important human xenosensor [1]. The Phase I
enzyme Cytochrome P450 3A4 (CYP3A4) [1] and its somewhat
less substrate-promiscuous paralog Cytochrome P450 3A5
(CYP3A5) [2] belong to the most prominent gene targets induced
by PXR. The various reactions catalyzed by CYP3A4 and
CYP3A5, most notably oxidations, facilitate Phase II conjugating
reactions and thereby the removal of xenobiotics from the body.
Substrates of these enzymes include an estimated 50% of
contemporary drugs [3,4].
The protective effects of the hepato-intestinal CYP3A induction
come at the expense of disturbed homeostatsis of important
metabolic processes. This is due to the participation of CYP3A in
the metabolism of steroid hormones, bile acids, and retinoids [1].
For example, the anti-tuberculosis drug and specific PXR agonist
rifampicin affects vitamin D homeostasis [5], leading to osteoma-
lacia [6]. This is consistent with the involvement of CYP3A4 and
CYP3A5 in the hepato-intestinal vitamin D metabolism [7,8,9].
The potential of homeostatic disturbances is particularly high
for CYP3A5 which, unlike CYP3A4, is expressed in the
steroidogenic organs prostate [10,11,12], adrenal gland [12],
and kidney [12,13]. The physiological significance of the
CYP3A5 expression in these organs is unknown, but could be
related to steroid metabolism. For example, the renal CYP3A5
expression level has been associated with salt-dependent
hypertension [14,15]. Besides proximal and distal tubules,
CYP3A5 is expressed in the collecting ducts [16,17,18], where
it is thought to affect the mineralocorticoid-driven sodium
reabsorption. The underlying mechanism is incompletely
understood but it could involve the mineralocorticoid effect of
6ß-hydroxylated glucocorticoids generated by CYP3A5 [19,20].
Additionally or alternatively, renal CYP3A5 activity could
regulate the glucocorticoid occupancy of mineralocorticoid
receptors [21]. Although the renal CYP3A5 expression level is
in all likelihood mainly determined by genetic polymorphisms
[22,23], its level in CYP3A5 expressors could be affected by
induction, similarly to what has been observed in the liver and
small intestine [2]. In addition to influencing endogenous
compounds such as steroids, CYP3A5 induction in the kidney
could exert medically important local effects on drug metabo-
lism. This can be inferred from the observation that microsomes
derived from CYP3A5-expressing kidneys faster inactivate the
immunosuppressive drug tacrolimus. This has been suggested to
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planted kidneys, which could accelerate their rejection [24].
CYP3A5-expressing kidneys also generate higher amounts of
nephrotoxic metabolites of drugs such as cyclosporine A [25] and
the alkylating agent ifosfamide [26].
The above considerations have spurred investigations of the
determinants of the CYP3A5 expression in tissues other than liver
and small intestine, and of the differential tissue expression of
CYP3A5 and CYP3A4 in general. The non-expression of
CYP3A4 as opposed to CYP3A5 in a lung-derived cell line has
been linked to a 57 bp insertion into the gene’s promoter, but the
exact mechanism has not been identified [27]. The expression of
CYP3A5 in the prostate has been reported to be mediated by a
promoter element binding the androgen receptor [10]. No
comparable investigations have been reported for the kidney
which, somewhat surprisingly, exhibits extremely low or non-
detectable expression of PXR transcripts [12,28,29,30,31,32,33].
Likewise, presently there is no data on CYP3A5 induction in
organs other than liver and small intestine [2].
Therefore, we investigated the determinants of the CYP3A5
expression, initially concentrating on the kidney as a model
organ. To this end, we first established a two-cell line model
reflecting the expression relationships of CYP3A4 and
CYP3A5 in the kidney and small intestine in vivo.O u rd a t a
demonstrate that the CYP3A5 expression in renal cells was
enabled by the loss of a suppressing yin yang 1 (YY1)-binding
site from the CYP3A5 promoter. This allowed for a renal, but
in all likelihood also adrenal and pulmonary CYP3A5
expression insensitive to PXR induction, as confirmed in
CYP3A5 transgenic mice. The YY1 element is retained in the
CYP3A4 promoter, but its effect is abrogated by PXR acting on
response elements such as the xenobiotic-responsive enhancer
module (XREM). The differential organ expression and
induction of CYP3A4 and CYP3A5 results thus from the loss
of the YY1 binding element from the CYP3A5 promoter, acting
in concert with the differential organ expression of PXR, and
with the higher accumulation of PXR response elements in the
CYP3A4 promoter.
Results
Evaluation of CYP3A5 and CYP3A4 proximal promoter
activities in renal and intestinal cells
The conservation of the primate CYP3A5 and CYP3A4
promoters is limited to their most proximal parts [34]. We
investigated if these parts are sufficient to confer the previously
reported differential expression of these genes in renal cells [12].
To this end we applied plasmids expressing firefly luciferase
under the control of CYP3A4 and CYP3A5 proximal promoter
fragments of comparable lengths of 374 and 370 bp, respec-
tively. These plasmids were transiently transfected into kidney-
derived cell line MDCK.2. These cells exhibit many character-
istics of tubular and collecting duct cells [35,36], which are the
site of CYP3A5 expression in humans [16,17]. The activity of
the CYP3A5 promoter was robust, whereas that of the CYP3A4
promoter was 31-fold lower (Figure 1A). On the other hand, the
activities of these promoters were similar in the small intestine-
derived cell line LS174T (Figure 1B). These findings were fully
compatible with the expression relationships between CYP3A4
and CYP3A5 in the human kidney and in the small intestine in
vivo [12]. Therefore, these cell lines were taken together as a
model for more detailed investigations of the determinants of
the differential renal and intestinal CYP3A4 and CYP3A5
expression.
Function of the 57 bp difference between the CYP3A4
and CYP3A5 promoters
The most prominent difference between the proximal CYP3A5
and CYP3A4 promoter sequences is the presence of a 57 bp
fragment in CYP3A4 which is absent from CYP3A5. This region is
Figure 1. The activities of proximal CYP3A4 (374 bp) and
CYP3A5 (370 bp) promoters in kidney-derived MDCK.2 cells
(A) and in small intestine-derived LS174T cells (B). Data are
expressed as mean values (6SEM) of six independent experiments
conducted as triplicates. Promoter-driven firefly luciferase activities in
the individual wells were normalized using activities of the co-
transfected renilla luciferase driven by a constitutive promoter.
Statistically significant differences are indicated by asterisks (*** p,
0.001).
doi:10.1371/journal.pone.0030895.g001
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box, the basic transcription element (BTE), the TATA-box, and
downstream of the everted repeat separated by 6 base pairs (ER6)
and the nuclear factor 1 (NF1) enhancer elements (Figure 2),
which have been characterized in previous studies [37,38,39].
Except NF1, all these elements are conserved between the CYP3A4
and CYP3A5 promoters. To determine the role of the 57 bp
fragment in the absence of CYP3A4 expression in renal cells, it was
deleted from the proximal CYP3A4 promoter. In parallel, this
sequence was replaced by one of identical length but with no
apparent transcriptional activity (‘‘spacer’’, SP in Figure 3). By
using a spacer we wanted to detect CYP3A4 promoter activity
changes independent from the content of the 57 bp fragment, but
related to any altered spatial interactions among surrounding cis-
acting elements following its deletion. Conversely, the CYP3A4-
derived 57 bp region, or alternatively the spacer, was inserted into
the corresponding location in the CYP3A5 promoter. The resulting
constructs (CYP3A4-57del, CYP3A4-57del/SPins, CYP3A5-57ins,
and CYP3A5-SPins, respectively) were assessed for activity in
MDCK.2 cells in parallel to the corresponding wild-type
promoters. The deletion of the 57 bp element increased the
activity of the CYP3A4 promoter 4-fold (Figure 3A). The
replacement of the 57 bp fragment with a spacer (CYP3A4-
57del/SPins construct) had a similar effect (Figure 3A). Converse-
ly, the CYP3A5-57ins construct exhibited a ,2/3 decrease in the
luciferase activity in comparison to the wild-type CYP3A5
promoter (Figure 3B), whereas no such effect was observed
following the spacer insertion.
Evolutionary history of the 57 bp region in primates
The above data demonstrated that the 57 bp fragment
contained elements repressing the activity of CYP3A promoters
in renal cells. In order to identify the responsible mechanism, the
57 bp region was investigated in more detail in silico and in vitro.T o
illuminate its evolutionary history and to increase the specificity of
the predicted regulatory elements, we first searched for homolog
sequences from several primate species. Homolog sequences were
found in both galago CYP3A genes (CYP3A91 and CYP3A92), in
both tarsier CYP3A genes, provisionally designated by us as gene A
and B (cont323625 and contig840032 of the genomic assembly
tarSyr1), in the CYP3A21 of the marmoset, as well as in all
CYP3A4, CYP3A7, and CYP3A43 genes from rhesus, chimpanzee,
and human (Figure 4A). Furthermore, sequences ortholog to the
57 bp fragment were identified in many non-primate mammalian
CYP3A genes (data not shown). In contrast, we found the 57 bp
fragment fully deleted from the promoters of all primate CYP3A5
genes (Figure 4A). In addition, a partial deletion of the most distal
25 bp within the 57 bp fragment was found in the tarsier gene B.
To verify if the repressive effect of the 57 bp region is conserved in
primates, ortholog sequences derived from the galago genes
CYP3A91 and CYP3A92 were inserted into the human CYP3A5
proximal promoter. Sequence from either gene repressed the
luciferase activity in renal cells.
The 57 bp region contains a conserved YY1-binding site
Besides a portion of the NF1-binding element and an E-box motif,
the 57 bp fragment contains on the anti-parallel strand a binding site
Figure 2. Sequence comparison and distribution of regulatory elements in the human CYP3A4 and CYP3A5 proximal promoters.
Identical nucleotides are denoted by asterisks. The 57 bp region absent from the CYP3A5 promoter is represented as a stretch of hyphens. The
transcription start sites [37,38] are indicated by arrows. The sequence is numbered relative to the transcription start site taken as +1. The binding sites
for previously characterized transcriptional regulators CCAAT-box, ER6, BTE, TATA-box, and NF1 [37,38,39] are underlined. The portion of the NF1
binding site described to constitute a CCAAT box, the YY1 site, and the two E-box motifs [27,39], all contained in the 57 bp region, are boxed. The
positions of binding sites are shown separately for CYP3A4 and, if applicable, in brackets for CYP3A5.
doi:10.1371/journal.pone.0030895.g002
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(Figure 2). YY1 binding to this element in the human CYP3A4
promoter had been reported previously [39], but its functional
significance was unknown. Considering the established role of YY1 as
a transcriptional repressor, we concentrated on the binding site for this
protein. YY1 is known to bind to a highly degenerated consensus
sequence 59-(C/g/a)(G/t)(C/t/a)CATN(T/a)(T/g/c)-39 with upper-
case and lowercase letters representing the preferred and tolerated
nucleotides, respectively. The bolded tri-nucleotide CAT constitutes
the YY1 binding core motif [40]. The highest concordance with the
consensus sequence was found in galago CYP3A91 and in marmoset
CYP3A21, which was reflected by the highest P-Match score values
(Figure 5). In contrast, all human, chimpanzee, and rhesus CYP3A4
and CYP3A7 promoters, as well as the promoter of the chimpanzee-
specific CYP3A67 gene and of the tarsier A gene contain the mismatch
T.C in the core motif CAT which is accompanied by decreased core
d-scores. The higher score values of CYP3A91,a sc o m p a r e dt o
CYP3A92, were in agreement with the stronger in vitro effects of the
57 bp insert derived from the former gene (Figure 4B).
Functional characterization of the human CYP3A4 YY1
binding site
We first confirmed the reported binding of YY1 to the
consensus binding site within the CYP3A4 promoter-derived
57 bp fragment [39] using an electrophoretic mobility gel shift
assay (EMSA). An IRDye800-labeled oligonucleotide encompass-
ing the CYP3A4 YY1 binding site served as a probe. A previously
described YY1-binding sequence from an unrelated gene [41] was
included as a positive control. A shifted complex was obtained for
the CYP3A4 YY1 region-derived oligonucleotide with MDCK.2
cell-derived nuclear extract (Figure 6). The complex migrated at
the same level as the YY1-DNA positive control complex. The
identity of the shift was confirmed with an anti-YY1 antibody,
which resulted in an immonodepletion. In contrast, an anti-PXR
antibody, included as a negative control, had no effect.
The functional importance of the CYP3A4-derived YY1 binding
site was then investigated in the CYP3A5 promoter context
(CYP3A5-57ins construct from Figure 3B) using mutagenesis
followed by transfection into MDCK.2 cells. Statistically signifi-
cant effects were observed with two mutants: The CYP3A5-
57insM1 mutant converts the imperfect YY1 core motif CAC into
a consensus motif CAT such as seen in galago CYP3A91 and in
marmoset CYP3A21. This enhanced the repression of the
promoter activity conferred by the 57 bp fragment (Figure 7A).
In the CYP3A5-57insM7 mutant, the core motif consensus
dinucleotide CA was replaced with the non-consensus dinucleotide
AG. Simultaneously, the dinucleotide TT outside the binding core
motif, implicated in the specificity of YY1 binding [42], was
Figure 3. The effect of the CYP3A4-derived 57 bp region on the activities of the proximal CYP3A4 and CYP3A5 promoters in MDCK.2
cells. (A) The effect of a deletion of the 57 bp region from the proximal CYP3A4 promoter, or of its replacement with an unrelated ‘‘spacer’’ (SP)
sequence of identical length. (B) The effect of the insertion of the 57 bp region, or of the ‘‘spacer’’ into the CYP3A5 promoter. Data are expressed as
mean values (6 SEM) of three to six independent experiments conducted as triplicates. Promoter-driven firefly luciferase activities in the individual
wells were normalized using activities of the co-transfected renilla luciferase driven by a constitutive promoter. Statistically significant differences are
indicated by asterisks (** p,0.01,*** p,0.001).
doi:10.1371/journal.pone.0030895.g003
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abolished the repressive effect of the 57 bp region on the CYP3A5-
driven luciferase but increased its activity 5-fold in comparison to
the wild-type CYP3A5 promoter (Figure 7A). As no such excessive
activity was observed with the ‘‘spacer’’ sequence (CYP3A5-Spins,
Figure 3B), this suggested the existence within the 57 bp fragment
of additional, as yet unidentified transcriptional enhancers which
come to light after the removal of the YY1-mediated repression.
Figure 4. Genomic and functional conservation of the 57 bp CYP3A promoter region in primates. (A) Representation of the evolution of
the 57 bp region. Deletions are shown as stretch of hyphens, with the widest one corresponding to the deletion of the entire 57 bp region. 1a–b and
2 indicate the two alternative scenarios of the 57 bp deletion. ‘‘CYP’’ has been removed from gene names to improve legibility. A 7 bp fragment
present only in all CYP3A43 genes has been removed for clarity and it position in the human CYP3A43 gene is indicated by an arrow. (B) The effect of
galago CYP3A91- and CYP3A92-derived 57 bp regions on the human CYP3A5 promoter activity in MDCK.2 cells. Data are expressed as mean values
(6SEM) of five independent experiments conducted as triplicates. Promoter-driven firefly luciferase activities in the individual wells were normalized
using activities of the co-transfected renilla luciferase driven by a constitutive promoter. Statistically significant differences are indicated by asterisks
*p,0.05, ***p,0.001.
doi:10.1371/journal.pone.0030895.g004
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putative E-box-like binding site [27] overlapping with the YY1-
binding site (Figure 2), had no effect on activity. Likewise, we saw
no changes in luciferase activity upon the mutation of the NF1 or
of the second, more downstream E-box binding site (Figure S1).
Taken together with the EMSA experiments (Figure 6), these
results demonstrated the existence of an YY1 binding site within
the 57 bp fragment of the CYP3A4 promoter which mediated
transcriptional repression in renal cells. They also suggested the
existence of as yet unidentified pro-transcriptional elements in this
fragment which are, however, fully suppressed by YY1.
The effects of YY1 and PXR on the CYP3A4 promoter
activity in intestinal cells
The loss of the YY1 response element from the CYP3A5
promoter and its retention in the CYP3A4 promoter were fully
consistent with the differential expression of these genes in renal
cells. However, this mechanism was in an apparent contrast with
the expression of CYP3A4 in small-intestinal cells LS174T
(Figure 2B) and in the small intestine in vivo [12]. We reasoned
that the absence of CYP3A4 repression in intestinal cells was
brought about by a mechanism overriding the repressive effect of
the YY1 binding element in the CYP3A4 promoter. In the most
parsimonious scenario, this could be achieved by the absence of
YY1 expression in intestinal cells. We tested this hypothesis by
measuring the expression of YY1 mRNA in either cell line. In
agreement with previous reports of an ubiquitous YY1 expression
[43] its mRNA was detected both in LS174T and MDCK.2 cells
(data not shown). An overexpression of YY1 in LS174T cells
approximately halved the luciferase activity driven by the CYP3A4
promoter (Figure S2). Furthermore, mutations of the YY1 site,
tested in LS174T cells in the CYP3A4 promoter context, showed
an identical response profile (Figure 7B and data not shown) as in
the CYP3A5 promoter context in MDCK.2 cells (Figure 7A). Thus,
the restoration of the consensus YY1 core motif (CYP3A4-M1)
significantly reduced, whereas the disruption of the site (CYP3A4-
M7) increased the CYP3A4 promoter activity (Figure 7B). Taken
together, these result suggested similar effects of YY1 in renal and
intestinal cells, arguing against the importance of this factor in the
differential expression of CYP3A4 in the kidney and small
intestine.
We then addressed the importance of the transcriptional CYP3A
regulator PXR, which is expressed in the small intestine, but not in
the kidney [12,28,29,30,31,32,33]. We hypothesized that PXR
may offset the inhibitory effect of YY1 on the CYP3A4 expression
in the small intestine. In this case, a similar effect could reasonably
Figure 5. Conservation and P-Match scores of the YY1 site in the 57 bp fragment of primate CYP3A promoters. The 59-VKHCATNWB-39
consensus for YY1 is depicted on the top of sequences in the IUB code. Nucleotides identical to the equivalence consensus are denoted by dots. The
arrow indicates the T.C mutation in the YY1 core motif. The phylogenetic tree of selected primate CYP3A genes on the left was adopted from a
previous study [68]. ‘‘CYP’’ has been removed from gene names to improve legibility.
doi:10.1371/journal.pone.0030895.g005
Figure 6. Binding of YY1 to the 57 bp element of the CYP3A4
promoter. Electrophoretic mobility shift assay of oligonucleotides
containing the CYP3A4-derived YY1 binding sequence incubated with
an MDCK.2 cells-derived nuclear extract (NE; 20 mg). The rpL30 gene-
derived oligonucleotide containing an unrelated, previously described
[41] YY1 binding site was used as a positive control. Reactions
contained (+) or lacked (2) the indicated component. The arrow points
to the YY1-DNA-binding complex. The immunodepletion was achieved
with an anti-YY1 antibody (1 mg). An anti-PXR antibody (300 ng) was
used as a negative control.
doi:10.1371/journal.pone.0030895.g006
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co-transfection of a PXR-expressing construct had only a weak
(two-fold increase) and statistically not significant effect on the
activity of the proximal CYP3A4 promoter (Figure 8). We then co-
transfected into these cells PXR together with the proximal
CYP3A4 promoter extended by the PXR-responsive enhancer
XREM present in the CYP3A4, but not in the CYP3A5 distal
promoter [34]. In this case, PXR resulted in a 13-fold increase in
the luciferase activity (Figure 8). Notably, the XREM inclusion
had no effect on the luciferase activity in the absence of PXR co-
transfection.
Differential induction of CYP3A5 in mouse tissues
The above observations were consistent with a PXR-regulated
expression of CYP3A5 (as well as of CYP3A4) in the small intestine,
and with a PXR-independent CYP3A5 expression in the kidney.
We hypothesized that these relationships would result in a
differential response of CYP3A5 in these organs to typical PXR
agonists in vivo. This was investigated in mice transgenic for firefly
luciferase driven by a 6.2 kb fragment of the human CYP3A5
proximal promoter. A detailed analysis of the strains generated by
two independent transgenic founders will be presented elsewhere.
The luciferase activities were similar in both strains and sexes and
the tissue distribution largely reflected that of CYP3A5 transcripts
in humans. The highest luciferase activity was detected in the
small intestine, followed by organs without PXR expression
[12,28,29,30,31,32,33] such as lung, adrenal gland, ovary, testis,
prostate, and kidney (Figure S3). In addition, luciferase was
detected in the forestomach, a structure absent in humans, and in
the adjacent oesophagus.
Transgenic mice of either sex were injected i.p. with 50 mg/kg
of the agonist of the murine PXR pregnenolone-16a-carbonitrile
(PCN) or with the dimethylsulfoxid (DMSO) solvent. Mice were
sacrificed by cervical dislocation 24 hours after treatment and
luciferase activities were determined in the homogenates of the
kidney, lung, adrenal gland, and of the duodenal part of the small
intestine. The CYP3A5 transgene was 3.7-fold induced by PCN in
the duodenum, whereas no induction was observed in the three
organs lacking PXR (Figure 9). In contrast to human kidneys
[12,28,29,30,31,32,33], mouse kidneys may express low levels of
Figure 7. Mutational analysis of the CYP3A4-derived YY1 binding site expressed (A) in MDCK.2 cells in the CYP3A5-57ins promoter
construct and (B) in LS174T cells in the native CYP3A4 promoter. The uppercase and lowercase letters represent preferred and tolerated
nucleotides, respectively. The bolded and underlined letters indicate the mutated nucleotides. The mutations either restore the consensus core motif
(M1), or progresively disrupt the YY1 binding site (M2 to M7). The construction of CYP3A4 and CYP3A5 mutants is described under ‘‘Materials and
Methods.’’ Promoter-driven firefly luciferase activities were normalized using activities of the co-transfected renilla luciferase driven by a constitutive
promoter and compared in (A) to that of the CYP3A5-ins57 construct and in (B) to that of the wild-type CYP3A4. Data are expressed as mean values
(6SEM) of four to eight independent experiments, conducted as triplicates. Statistically significant differences are indicated by asterisks
(** p,0.01,*** p,0.001).
doi:10.1371/journal.pone.0030895.g007
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[45,46]. To minimize the risk of overlooking the CYP3A5
induction in this organ, we exposed our transgenic mice to a still
higher PCN dose of 100 mg/kg. The induction in the duodenum
increased to 7-fold, but it was still absent from the kidney.
Similarly to the 50 mg/kg dose, we observed no sex-dependent
differences in the PCN response (data not shown).
Discussion
Considering the expression of CYP3A5 in several steroidogenic
organs, reports of its induction by PXR seemed paradoxical, as
enhanced CYP3A5 activity could affect the steroid homeostasis.
Admittedly, it has been noticed that aside from liver and small
intestine, CYP3A5 is expressed exclusively in organs devoid of
PXR expression [12], so that induction could be restricted to the
former two organs. However, this in turn raises questions about
the mechanism of CYP3A5 expression outside liver and small
intestine, as the importance of PXR in CYP3A regulation is
paramount. In the present work we illuminate these issues by
demonstrating that the expression of CYP3A5 in most organs
expressing this enzyme is indeed independent from PXR and in
consequence irresponsive to the latter one’s ligands, at least in
transgenic mice. This constitutes a first description of uncoupling
induction from constitutive expression for a major detoxifying
enzyme, and of the underlying mechanism.
The expression of CYP3A5 in organs lacking PXR appears to
be enabled by the loss of a suppressive YY1-binding element from
the CYP3A5 promoter during primate evolution. To arrive at this
conclusion, we applied a combination of in vitro, in vivo, and
transgenic techniques. We first established a two-cell line model of
the small intestine and kidney, two organs expressing CYP3A5.
The LS174T cells have been repeatedly validated as a faithful
model of the basal and drug-induced CYP3A expression in the
small intestine [34,47], including the induction of CYP3A5 [2].
The MDCK.2 cells exhibit many characteristics of the collecting
duct cells, a principal site of CYP3A5 expression in the kidney
[16,17,18]. Transfected with CYP3A4 and CYP3A5 promoter
constructs, these cell lines fully reflected the expression relation-
ships between these genes in the kidney and small intestine [12],
with both genes expressed at similar levels in small intestinal, but
only CYP3A5 in renal cells.
The importance of YY1 in the expression of CYP3A5 in renal
cells is supported by several lines of complementary evidence
obtained from mutated CYP3A5 promoter constructs, from
comparisons to the CYP3A4 promoter, and from chimeras
comprising elements of both promoters. Thus, the CYP3A4-
derived 57 bp fragment comprising a consensus YY1-binding site
inserted into the CYP3A5 promoter inhibited its transcriptional
activity in renal cells. Conversely, its deletion from the CYP3A4
promoter derepressed the luciferase activity in the same cell line.
The specific involvement of YY1 in these effects was demonstrated
by the effects of its mutagenesis, which mimicked the transcrip-
tional effects of the entire 57 bp fragment. Thus, mutations
designed to disrupt the YY1-binding site increased the activities of
the CYP3A4 and CYP3A5 promoters, whereas optimizing the core
sequence of the YY1 site had an opposite effect. Lastly, this
sequence bound YY1 [39], as confirmed in our study.
YY1 is a ubiquitously expressed and evolutionary conserved
member of the GLI-kru ¨ppel family of zinc finger transcription
factors [43], which have been implicated in the transcriptional
regulation of numerous genes important for cell proliferation,
differentiation, and metabolism [48]. Depending upon the
Figure 8. The effect of PXR overexpression on the XREM-CYP3A4-driven luciferase activity in MDCK.2 cells. The wild-type 374 bp
CYP3A4 and the chimeric XREM-CYP3A4 constructs were transiently transfected in MDCK.2 cells. (+) and (2) indicate transfection with a PXR-
expressing plasmid and with the same empty plasmid, respectively. Data are expressed as mean values (6 SEM) of three to five independent
experiments conducted as triplicates. Promoter-driven firefly luciferase activities in the individual wells were normalized using activities of the co-
transfected renilla luciferase driven by a constitutive promoter. Statistically significant differences are indicated by asterisks (*** p,0.001).
doi:10.1371/journal.pone.0030895.g008
Figure 9. The effect of PCN on the expression of firefly
luciferase driven by 6.2 kb of a human CYP3A5 promoter in
the duodenum, kidney, adrenal gland, and lung of transgenic
mice. Mice (3 males and 3 females per treatment group) were injected
i.p. with PCN (50 mg/kg) or the DMSO solvent. Organ homogenates
were assayed with luciferase reporter gene assay (Promega) using a
luminometer. Data are represented as ratio of RLU per mg protein of
PCN over DMSO, shown as mean values (6 SEM). Statistically significant
differences are indicated by asterisks (*** p,0.001).
doi:10.1371/journal.pone.0030895.g009
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activator or repressor [43], with the last-mentioned function
apparently applying to CYP3A. YY1 may repress transcription
directly, indirectly via cofactor recruitment or displacement, or via
conformational DNA changes [49] and the elucidation of the
exact mechanism applying to CYP3A requires further detailed
studies.
The CYP3A YY1 binding site predates primate origin and its
suppressing function seems to be conserved across primates, as
demonstrated by a comparison of the ortholog elements from
human and galago. We speculate that this regulatory element
originally may have helped to restrict the tissue spectrum of
CYP3A expression. This may have been important for the
homeostasis of endobiotics such as steroid hormones, some of
which (testosterone, corticosterone, progesterone and androstene-
dione) are proven CYP3A substrates [1,21,50,51]. The YY1
binding site was deleted from the CYP3A5 gene lineage together
with additional sequence altogether comprizing 57 bp of the
promoter sequence. This deletion occurred early in Haplorrhini
following the separation from Strepsirrhini via one of two alternative
two-step scenarios (Figure 4A). In one scenario, the first step
comprised the more distal 25 bp and occurred in the common
ancestor of Tarsiiformes and Simiiformes (i.e. some 57 million years
ago), as indicated by a 25 bp deletion found in one of the two
tarsier genes. Following the separation of Tarsiiformes and
Simiiformes, the more proximal part was subsequently lost in a
common ancestor of the latter primate infraorder. This occurred
not later than 40 million years ago, since the 57 bp deletion is
detected in both parvorders of Simiiformes, i.e. in Old World
monkeys (human, chimpanzee, rhesus), and in New World
monkeys represented by the marmoset. The second scenario
comprises two independent deletions of different lengths, but of
the same distal boundary occurring in Tarsiiformes and Simiiformes
following their separation (Figure 4A). In either case, the 57 bp
fragment was lost from the entire CYP3A5 gene repertoire and not
inserted into the human CYP3A4 promoter, as suggested
previously by a comparison of exclusively human CYP3A4 and
CYP3A5 promoter sequences [27,52]. The 10 bp deletion partly
overlapping with the 57 bp deletion found in the chimpanzee
CYP3A67 was apparently an unrelated event, as judged from the
intact sequence in the corresponding region in its closest paralog
genes, i.e. CYP3A7.
Based on the cell line data we predicted a differential response
of CYP3A5 in the kidney and small-intestine to PXR-driven
induction. We reasoned that since in the mouse PXR is strongly
expressed in the small intestine but at best weakly in the kidney
[32,44], the CYP3A5 promoter activity would be enhanced by
PXR agonists in the former, but unaffected in the latter organ.
This prediction was verified and confirmed in mice expressing
firefly luciferase under the control of a CYP3A5 promoter
fragment. For mouse transgenesis we used a larger (6.2 kb)
CYP3A5 promoter fragment to maximize the chances to
recapitulate the CYP3A5 tissue expression in humans. Indeed,
while our cell line data suggest that the loss of YY1-mediated
repression was necessary for CYP3A5 expression in organs lacking
PXR such as the kidney, this loss could not be the only
determinant of the CYP3A5 organ expression, as this expression
is ubiquitous neither in humans nor in our transgenic mice. While
the identification of other determinants of the CYP3A5 tissue
expression spectrum will require further studies, most of them are
bound to be contained within the 6.2 kb CYP3A5 promoter
fragment. This is indicated by the striking similarity between the
tissue distribution of the luciferase in our transgenic mice and the
CYP3A5 expression in humans. The only major difference is the
absence of luciferase expression in the liver, which suggests the
existence of a liver-specific enhancer outside the promoter
fragment used for transgenesis. There is increasing evidence that
gene clusters are co-regulated [53] and it is tempting to speculate
that the liver expression of CYP3A5 may require an enhancer
shared with the other CYP3A genes, which form a cluster on
chromosome 7.
The differential changes in luciferase activity in the kidney and
small intestine in response to the mouse PXR agonist PCN is in
agreement with the observations by Cheng and Klaassen, who
detected an intestinal, but not renal, induction of the mouse gene
Cyp3a11 in response to the same compound [44]. Since the PXR
expression in human kidneys is either non-detectable or at least
much lower than in mouse kidneys, we infer that CYP3A5 in
human kidneys is similarly irresponsive to PXR activators. This is
consistent with the failure of the agonist of the human PXR
rifampicin to affect the renal activity of the PXR target P-
glycoprotein in human subjects [54]. In turn, the small-intestinal
induction of CYP3A5 in our transgenic mice in response to PCN is
in agreement with the upregulation of this gene in small intestines
of humans treated with the agonist of the human PXR rifampicin
[2].
Besides the kidney, CYP3A5 induction was also absent from the
adrenal gland and lung, i.e. tissues, which in humans and mice
exhibit none or at best a very low level of PXR [12,28,29,
30,31,32,33,45]. This suggests that the CYP3A5 expression in
human organs unrelated to xenobiotic response (i.e. other than
small intestine and liver) may be generally irresponsive to PXR-
mediated induction, as already demonstrated for the kidney [54].
Furthermore, we speculate that the loss of the YY1-mediated
transcriptional repression may have enabled the constitutive
CYP3A5 expression in all organs expressing this enzyme aside
from liver and small intestine. This speculation is strongly
supported by the findings by Biggs et al. [27], which provided
one of the starting points and many experimental ideas for our
investigation. These workers demonstrated a derepression of a
CYP3A5 promoter activity in a lung-derived cell line upon
deletion of the same 57 bp fragment as in our study. The loss of
the YY1-mediated transcriptional repression may have thus
allowed for the widening of the CYP3A5 tissue expression in the
absence of induction. This has allowed on the one hand, for
avoiding the deleterious effects of CYP3A5 induction on the
homeostasis of any endogenous substrates of the CYP3A5 protein,
such as steroids. On the other hand, the CYP3A5 expression
outside the liver and small intestine must have conferred fitness
advantages, which remain to be identified. Renal CYP3A5
expression may have enhanced salt and water retention mediated
by CYP3A5-catalyzed 6b-hydroxycortisol, which may have been
advantageous in a hot climate. This mechanism has been
suggested to be responsible for the high prevalence of the gene
polymorphism-driven CYP3A5 expression in Africans, most of
which express CYP3A5 in the kidney, perhaps at the expense of an
increased risk of salt-dependent hypertension [55]. Taken
together, the PXR-independent CYP3A5 expression outside the
liver and small intestine may have evolved in primates to employ
this enzyme in endobiotic homeostasis protected against poten-
tially deleterious effects of xenobiotic-driven induction. To our
knowledge, this is a first evolutionary description of the mechanism
uncoupling the inducible and constitutive expression in a major
detoxifying enzyme. Similar mechanisms may have evolved for
other detoxifying proteins, many of which metabolize endobiotics.
Although this work focuses on CYP3A5, some of our
observations illuminate the regulation of CYP3A4, which is
expressed concomitantly with CYP3A5 in the liver and small
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presence of a transcriptionally repressive YY1 element in the
CYP3A4 promoter seemed to be at odds with the expression of
CYP3A4 in these organs. Subsequent experiments designed to
resolve this contradiction suggest that the inhibitory effect of YY1
on CYP3A4 promoter activity is overridden, at least in small-
intestinal cells, by the concerted action of one trans- and one cis-
acting factor. We have identified these factors using MDCK.2
cells, which normally do not support CYP3A4 expression, due to
the inhibitory effect of the YY1 on its promoter. Through co-
transfection of the transcriptional CYP3A regulator and xenobi-
otic sensor PXR, we conferred onto these cells a capability to
express CYP3A4. PXR is normally expressed in the small intestine,
but not in the kidney [12,28,29,30,31,32,33]. This suggests that
the expression of PXR, acting in trans, is an indispensable
determinant of the CYP3A4 expression in organs such as small
intestine.
Besides PXR, the expression of CYP3A4 in MDCK.2 cells
required the presence of the PXR-responsive, cis-acting element
XREM, located in the distal part of the CYP3A4 promoter.
Together with the proximal ER6 (Figure 2) and the far-distal
constitutive liver enhancer module (CLEM), XREM represents
the original scheme of CYP3A regulation by nuclear receptors
such as PXR in placental mammals [34]. The need to offset the
inhibitory effect of YY1 may have been the force driving both the
conservation of XREM and the origin of novel PXR-responsive
elements outside XREM recently described in the CYP3A4 gene
lineage [34]. Conversely, the loss of XREM from the CYP3A5 gene
lineage [34] is consistent with the reduced pressure to maintain
XREM, conferred by the loss of the transcriptionally repressive
YY1 binding site. In support of this interpretation, the losses of the
YY1 binding element (Figure 4A) and of XREM [34] from the
CYP3A5 gene lineage occurred simultaneously in evolutionary
terms, since they are restricted to Haplorrhini.
The XREM-mediated, CYP3A4 expression-promoting effect of
PXR may have been additionally facilitated by the apparent
attenuation of the YY1 inhibitory effect. This attenuation is
conferred by the mutation of the YY1 consensus site core sequence
CAT.CAC, which is present in all Haplorrhini CYP3A genes
containing this element, except the pseudogene CYP3A43. The
importance of this mutation was suggested by the diminished score
values and confirmed by mutagenesis. The results of this latter
experiment suggest that the sequence change in the YY1 core
sequence may contribute to the high expression level of CYP3A4
in humans. This mutation may contribute to the differential
expression of CYP3A4 and CYP3A5 in the small intestine and
kidney in humans, acting in concert with the loss of the YY1
binding element from the CYP3A5 promoter together with the
differential organ expression of PXR and the higher accumulation
of ancestral PXR response elements in CYP3A4.
We are aware of several shortcomings of our investigations. For
example, transient transfections may not adequately recapitulate
gene regulation in a natural chromatin context. On the other
hand, both our cell line-derived data as well as those by Biggs and
colleagues [27] are fully consistent with the CYP3A5 organ
expression and with the response to PXR activators in transgenic
mice and in selected human organs such as small intestine, liver
[2], and kidney [54]. Likewise, our results from transgenic mice do
not formally prove the role of YY1 in the differential expression of
CYP3A4 and CYP3A5 in human organs. They were conducted
primarily to test the prediction of the differential organ induction
of CYP3A5. However, this role is strongly suggested by the
accumulating data on the effects of the YY1 site on promoter
activity in cell lines derived from three relevant human organs
(lung [27], small intestine, and kidney). Taken together, YY1
formally affects the activity of CYP3A promoters analyzed in cell
lines. However, its effects are fully consistent with the available
information on the differential organ expression and induction of
CYP3A5 and CYP3A4 in vivo.
Materials and Methods
Chemicals
PCN and DMSO were obtained from Sigma (St. Louis, MO).
D-Luciferin was purchased from BD Gentest (Woburn; MA). All
other chemicals used in this study are commercially available
molecular biology grade.
Cell Culture, Transient Transfection and Luciferase
Reporter Gene Assay
Human colon carcinoma-derived LS174T cells [56] and the
canine kidney-derived MDCK.2 cells [57], were obtained from
American Type Culture Collection. Both cell lines were
maintained as described for LS174T cells [58], except that the
MDCK.2 cell culture medium lacked the 1% essential amino acid
supplement. LS174T and MDCK.2 cells were transfected using
the Gene Juice transfection reagent (Novagen) and luciferase
activities measured as described [59]. In PXR transactivation
experiments 10 ng of the plasmid pcDhuPXR [60] were co-
transfected.
CYP3A Promoter Sequence Analysis
Approximately 1 kb of CYP3A sequence upstream from exon 1
from human (Homo sapiens), rhesus (Macaca mulatta), and
chimpanzee (Pan troglodytes) was downloaded via Ensemble
genome browser or NCBI Genbank. The corresponding sequenc-
es from marmoset (Callithrix jacchus) CYP3A5, CYP3A21 and
CYP3A90, and the galago (Otolemur garnetti) CYP3A91 and
CYP3A92 genes were obtained from bacterial artificial chromo-
some (BAC) sequences (CH259-48H24 and CH256-241K21),
respectively [61]. Tarsier (Tarsius syrichta) sequences were
identified from the whole-genome shotgun sequence database in
NCBI using BLASTn [62]. Sequence alignment was performed
using Multi-LAGAN [63] and visualized in BIOEDIT [64]. P-
Match [65] was used for identification and scoring of YY1 DNA
response elements. Matching was performed to predefined
vertebrate matrices in a liver specific profile.
Construction of Reporter Gene Constructs
The proximal 370 bp of the CYP3A5 promoter were amplified
from the BAC clone 22300 [66] with NcoI- and NarI-extended
primers (Table S1). The digested and gel-extracted (Gene Jet gel
extraction kit, Fermentas) PCR product was ligated to the
analogously digested pGL3-Basic vector (Promega). CYP3A5-luc
transgenic mice were generated via pronuclear injection of a
plasmid expressing firefly luciferase under the control of the
proximal 6.2 kb of the human CYP3A5 promoter. To this end, a
5.4 kb and a 555 bp fragment of the human CYP3A5 promoter
were amplified from the BAC clone 22300 with MluI/NcoI and
KpnI/AvrII extended primers (Table S1), sequentially sub-cloned
into the CYP3A5-370 construct and confirmed by sequencing.
The 374 bp CYP3A4 promoter construct and the chimerical
XREM-CYP3A4 construct were described previously [58,67].
Inverted PCR-based Mutagenesis
The insertions and deletions into the wild-type CYP3A5 and
CYP3A4 promoter constructs were generated using an inverted
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Table S1. Insertion primers were 39-complementary to the
template plasmid and 59-extended by the sequence to be inserted.
PCR products amplified with the High Fidelity Taq polymerase
(Bioline) were subjected to DpnI digestion (Fermentas) to remove
the dam-methylated parental templates. After purification on a
column (Fermentas), PCR products were further digested with
Mung Bean exo-nuclease (New England Biolabs) for 90 minutes to
obtain blunt ends for the subsequent ligation using a T4 ligase
(New England Biolabs).
Site-directed Mutagenesis of the YY1 Binding Site
All mutations were introduced into the CYP3A5-57ins and
CYP3A4-374 constructs using the QuikChange Site-Directed
Mutagenesis Kit (Stratagene), according to manufacturer’s in-
structions, and primers listed in Table S2. All clones used in
transfection experiments were confirmed by sequencing.
Nuclear Extract Preparation
Confluent MDCK.2 cells were washed twice with ice-cold PBS,
and detached using a rubber policeman in 1 ml of the hypotonic
buffer A, consisting of 10 mM HEPES (pH 7.9), 10 mM KCl,
0.1 mM EGTA, 0.1 mM EDTA, 0.1% benzoase (Novagen) and
2% EDTA-free protease inhibitor cocktail (Calbiochem). Cells
were pelleted at 750 g for 5 min, resuspended in 1 ml of buffer A
with 0.4% IGEPAL (Sigma) and kept on ice for 15 min for cell
swelling and membrane lysis. After gentle centrifugation, the
nuclear pellet was resuspended in 100 ml of an ice-cold hypertonic
buffer (Buffer B: 20 mM HEPES (pH 7.9), 0.4 M NaCl, 1 mM
EDTA, 1 mM EGTA, 1 mM dithiothreitol, 0.1% benzoase, 2%
EDTA-free protease inhibitor cocktail) and vigorously mixed for
60 minutes at 4uC to disrupt the nuclear membrane. This was
followed by centrifugation at 7,500 g for 15 minutes at 4uCt o
remove nuclear debris. The supernatant (nuclear extract) was
collected and stored in aliquots at 280uC. Protein concentration
was determined by the Bradford method. The enrichment of
nuclear proteins was confirmed by Western blot using antibodies
against a nucleus-specific (lamin B) and a cytosol-specific
(GAPDH) protein (data not shown).
Electrophoretic Mobility Gel Shift Assay
A nucleotide containing the (underlined) YY1 consensus
binding site from the CYP3A4 promoter (ttggaagaggcttctccaccttg-
gaagttggca), a positive YY1 control (cgctccgcggccatcttggcggctggt),
and the respective complement oligonucleotides were 59-labelled
with IRDye 800 (Metabion). The positive control contains a
previously reported YY1-binding site [41]. Equimolar amounts of
complementary oligonucleotides were annealed by boiling for
5 minutes at 100uC followed by slow cooling to room temperature.
Thus obtained double-stranded labeled probes were diluted with
double-desalted water and stored in aliquots at 220uC in light-
protected tubes until use. EMSA reactions contained 10 mM
HEPES (pH 7.9), 60 mM KCl, 0.2% IGEPAL (Sigma), 6%
Glycerol, 2 mM dithiothreitol, 1 mg poly d(I-C) (Sigma), 20 mgo f
nuclear extract, 50 fmol of a ID800-labeled probe in a total
volume of 10 ml. Supershift reactions additionally included 1 mgo f
the anti-YY1 (sc-73416) or 300 ng of the anti-PXR (sc-7737)
antibodies (Santa Cruz Biotechnology). Reactions were pre-
incubated 15 minutes or, for supershift, 30 minutes at room
temperature and incubated for further 20 minutes after the
addition of the labeled probe in a volume of 2.5 ml. Samples were
subsequently resolved by native PAGE in a pre-run 4% minigel in
0.56TBE at 100 Volt for 60 minutes at 4uC and visualised with
an Odyssey infrared imager (LI-COR Biosciences) with focus
offset at 0.375 mm.
Generation of CYP3A5-luciferase Transgenic Mice
Two transgenic lines were established by pronuclear injection of
a plasmid expressing firefly luciferase under the control of the
proximal 6.2 kb of the human CYP3A5 promoter (see above). Two
founders were identified by Southern blotting (data not shown).
The transgene was kept on the original genetic background
C57BL/6J by breeding heterozygous carriers with wild-type
C57BL/6J mice. Transgenic mice were identified by PCR of
genomic DNA isolated from mice tail tips, using primers CYP3A5-
Fw and CYP3A5-Rv primers listed in Table S1, which generate a
500 bp PCR amplicon. Transgenic and wild-type mice were
housed in our animal facility and maintained under controlled
environmental conditions with a 12 h/12 h light/dark cycle. Food
and water were available ad libitum.
Transgenic Mice Treatment
All animals experiment described in this study were approved by
the responsible animal ethics committee. Male and female 6 to 8
weeks old transgenic mice weighing 20 to 29 g were used to
determine the effect of PCN on the CYP3A5-luc transgene activity
in the duodenum and kidney in vivo. Mice (n=3 per group and sex)
were injected i.p. with 50 or 100 mg/kg of the murine PXR agonist
PCN dissolved in DMSO. Control mice were injected with DMSO
only. Mice were sacrificed by cervical dislocation 24 hours after the
treatment. Tissue samples were rapidly removed, washed in ice-cool
16PBS, snap-frozen in liquid nitrogen, and stored at 280uC until
used. Tissues were homogenized by at least ten strokes of a tissue
disrupter (Ultraturrax) in 200–500 ml of a cell lysis buffer (Promega).
Homogenates were shock-frozen in liquid nitrogen, thawed and
subsequently centrifuged at 5000 g for 5 minutes at 4uC. The
supernatant was collected for measurement of luciferase activity.
Protein concentration was determined by the Bradford method.
Luciferase activity was determined as described above and
expressed as relative light units (RLU) per mg of total protein.
Statistical Analyses
Statistically significant differences were calculated with Mann-
Whitney U test or one-way ANOVA with a Dunnett’s post-test if
applicable. All tests were performed using GraphPad Prism
version 5.0 (GraphPad Software, San Diego, CA). Results were
considered as statistically significant at P values,0.05.
Supporting Information
Figure S1 Mutational analysis of the NF1 and the E-box
in CYP3A4 and CYP3A5-57ins constructs in MDCK.2
cells. The mutations either restore the NF1 consensus core motif
(CYP3A5-ins57NF1/SP) or disrupt the NF1 (CYP3A4-NF1M) or the
E-box site (CYP3A4-EboxM and CYP3A5-57insEboxM). Mutants,
wild-type CYP3A4 (A), and CYP3A5 (B) promoter constructs were
transiently transfected into MDCK.2 cells. Promoter-driven firefly
luciferase activities were normalized using activities of the co-
transfected renilla luciferase driven by a constitutive promoter and
compared to that of the wild type construct. Data are expressed as
mean values (6SEM) of four independent experiments conducted
as triplicates. Statistically significant differences are indicated by
asterisks (***p,0.001).
(TIF)
Figure S2 The effect of YY1 overexpression on the
CYP3A4-driven luciferase activity in LS174T cells. The
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LS174T cells. (+) and (2) indicate transfection with an YY1-
expressing plasmid and with the same empty plasmid, respectively.
Data are expressed as mean values (6 SEM) of eight independent
experiments conducted as triplicates. Promoter-driven firefly
luciferase activities in the individual wells were normalized using
activities of the co-transfected renilla luciferase driven by a
constitutive promoter. The statistically significant difference is
indicated by asterisks (*** p,0.001).
(TIF)
Figure S3 Tissue distribution of the luciferase activity of the
CYP3A5-luc transgene. Organs were isolated from transgenic mice
(n=4 per group) from line A (TGA) and line C (TGC). Organ
homogenates were assayed with a luciferase reporter gene assay
(Promega) using a luminometer. Data from female (A) and male
(B) are relative light units (RLU)/mg protein, shown as mean
values 6SEM.
(TIF)
Table S1 Oligonucleotides used for cloning of the
CYP3A5 proximal promoter constructs (1 to 6), PCR
genotyping of the transgenic mice (7 and 8), and for
insertions and deletions (9 to 16).
(PDF)
Table S2 Oligonucleotides used for site-directed muta-
genesis of the YY1 binding site.
(PDF)
Acknowledgments
We thank Prof. Kurt Reifenberg for the pronuclear injections to generate
the transgenic CYP3A5 mouse strains. We are grateful to Dr. Oliver Burk
and Dr. Nakoa Tanese for the 374 bp CYP3A4 construct and the YY1
expression vector, respectively.
Author Contributions
Conceived and designed the experiments: LW DN DB. Performed the
experiments: DN DB UGA SN. Analyzed the data: LW DB HQ DN.
Wrote the paper: LW DB DN HQ.
References
1. Ihunnah CA, Jiang M, Xie W (2011) Nuclear receptor PXR, transcriptional
circuits and metabolic relevance. Biochim Biophys Acta 1812: 956–963.
2. Burk O, Koch I, Raucy J, Hustert E, Eichelbaum M, et al. (2004) The induction
of cytochrome P450 3A5 (CYP3A5) in the human liver and intestine is mediated
by the xenobiotic sensors pregnane X receptor (PXR) and constitutively
activated receptor (CAR). J Biol Chem 279: 38379–38385.
3. Shimada T, Yamazaki H, Mimura M, Inui Y, Guengerich FP (1994)
Interindividual variations in human liver cytochrome P-450 enzymes involved
in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver
microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 270:
414–423.
4. Li HC, Dehal SS, Kupfer D (1995) Induction of the hepatic CYP2B and CYP3A
enzymes by the proestrogenic pesticide methoxychlor and by DDT in the rat.
Effects on methoxychlor metabolism. J Biochem Toxicol 10: 51–61.
5. Brodie MJ, Boobis AR, Dollery CT, Hillyard CJ, Brown DJ, et al. (1980)
Rifampicin and vitamin D metabolism. Clin Pharmacol Ther 27: 810–814.
6. Shah SC, Sharma RK, Hemangini, Chitle AR (1981) Rifampicin induced
osteomalacia. Tubercle 62: 207–209.
7. Gupta RP, He YA, Patrick KS, Halpert JR, Bell NH (2005) CYP3A4 is a
vitamin D-24- and 25-hydroxylase: analysis of structure function by site-directed
mutagenesis. J Clin Endocrinol Metab 90: 1210–1219.
8. Gupta RP, Hollis BW, Patel SB, Patrick KS, Bell NH (2004) CYP3A4 is a
human microsomal vitamin D 25-hydroxylase. J Bone Miner Res 19: 680–688.
9. Xu Y, Hashizume T, Shuhart MC, Davis CL, Nelson WL, et al. (2006) Intestinal
and hepatic CYP3A4 catalyze hydroxylation of 1alpha,25-dihydroxyvitamin
D(3): implications for drug-induced osteomalacia. Mol Pharmacol 69: 56–65.
10. Moilanen AM, Hakkola J, Vaarala MH, Kauppila S, Hirvikoski P, et al. (2007)
Characterization of androgen-regulated expression of CYP3A5 in human
prostate. Carcinogenesis 28: 916–921.
11. Lash LH, Putt DA, Cai H (2008) Drug metabolism enzyme expression and
activity in primary cultures of human proximal tubular cells. Toxicology 244:
56–65.
12. Koch I, Weil R, Wolbold R, Brockmoller J, Hustert E, et al. (2002)
Interindividual variability and tissue-specificity in the expression of cytochrome
P450 3A mRNA. Drug Metab Dispos 30: 1108–1114.
13. Haehner BD, Gorski JC, Vandenbranden M, Wrighton SA, Janardan SK, et al.
(1996) Bimodal distribution of renal cytochrome P450 3A activity in humans.
Mol Pharmacol 50: 52–59.
14. Ho H, Pinto A, Hall SD, Flockhart DA, Li L, et al. (2005) Association between
the CYP3A5 genotype and blood pressure. Hypertension 45: 294–298.
15. Kreutz R, Zuurman M, Kain S, Bolbrinker J, de Jong PE, et al. (2005) The role
of the cytochrome P450 3A5 enzyme for blood pressure regulation in the general
Caucasian population. Pharmacogenet Genomics 15: 831–837.
16. Aleksa K, Matsell D, Krausz K, Gelboin H, Ito S, et al. (2005) Cytochrome
P450 3A and 2B6 in the developing kidney: implications for ifosfamide
nephrotoxicity. Pediatr Nephrol 20: 872–885.
17. Joy MS, Hogan SL, Thompson BD, Finn WF, Nickeleit V (2007) Cytochrome
P450 3A5 expression in the kidneys of patients with calcineurin inhibitor
nephrotoxicity. Nephrol Dial Transplant 22: 1963–1968.
18. Murray GI, McFadyen MC, Mitchell RT, Cheung YL, Kerr AC, et al. (1999)
Cytochrome P450 CYP3A in human renal cell cancer. Br J Cancer 79:
1836–1842.
19. Matsuzaki K, Arai T, Miyazaki T, Yasuda K (1995) Formation of 6 beta-OH-
deoxycorticosterone from deoxycorticosterone by A6 cells. Steroids 60: 457–462.
20. Clore J, Schoolwerth A, Watlington CO (1992) When is cortisol a
mineralocorticoid? Kidney Int 42: 1297–1308.
21. Morris DJ, Latif SA, Rokaw MD, Watlington CO, Johnson JP (1998) A second
enzyme protecting mineralocorticoid receptors from glucocorticoid occupancy.
Am J Physiol 274: C1245–1252.
22. Hustert E, Haberl M, Burk O, Wolbold R, He YQ, et al. (2001) The genetic
determinants of the CYP3A5 polymorphism. Pharmacogenetics 11:
773–779.
23. Kuehl P, Zhang J, Lin Y, Lamba J, Assem M, et al. (2001) Sequence diversity in
CYP3A promoters and characterization of the genetic basis of polymorphic
CYP3A5 expression. Nat Genet 27: 383–391.
24. Dai Y, Hebert MF, Isoherranen N, Davis CL, Marsh C, et al. (2006) Effect of
CYP3A5 polymorphism on tacrolimus metabolic clearance in vitro. Drug Metab
Dispos 34: 836–847.
25. Dai Y, Iwanaga K, Lin YS, Hebert MF, Davis CL, et al. (2004) In vitro
metabolism of cyclosporine A by human kidney CYP3A5. Biochem Pharmacol
68: 1889–1902.
26. McCune JS, Risler LJ, Phillips BR, Thummel KE, Blough D, et al. (2005)
Contribution of CYP3A5 to hepatic and renal ifosfamide N-dechloroethylation.
Drug Metab Dispos 33: 1074–1081.
27. Biggs JS, Wan J, Cutler NS, Hakkola J, Uusimaki P, et al. (2007) Transcription
factor binding to a putative double E-box motif represses CYP3A4 expression in
human lung cells. Mol Pharmacol 72: 514–525.
28. Lehmann JM, McKee DD, Watson MA, Willson TM, Moore JT, et al. (1998)
The human orphan nuclear receptor PXR is activated by compounds that
regulate CYP3A4 gene expression and cause drug interactions. J Clin Invest 102:
1016–1023.
29. Nishimura M, Naito S, Yokoi T (2004) Tissue-specific mRNA expression profiles
of human nuclear receptor subfamilies. Drug Metab Pharmacokinet 19:
135–149.
30. Lamba V, Yasuda K, Lamba JK, Assem M, Davila J, et al. (2004) PXR (NR1I2):
splice variants in human tissues, including brain, and identification of
neurosteroids and nicotine as PXR activators. Toxicol Appl Pharmacol 199:
251–265.
31. Bertilsson G, Heidrich J, Svensson K, Asman M, Jendeberg L, et al. (1998)
Identification of a human nuclear receptor defines a new signaling pathway for
CYP3A induction. Proc Natl Acad Sci U S A 95: 12208–12213.
32. Kliewer SA, Moore JT, Wade L, Staudinger JL, Watson MA, et al. (1998) An
orphan nuclear receptor activated by pregnanes defines a novel steroid signaling
pathway. Cell 92: 73–82.
33. Blumberg B, Sabbagh W, Jr., Juguilon H, Bolado J, Jr., van Meter CM, et al.
(1998) SXR, a novel steroid and xenobiotic-sensing nuclear receptor. Genes Dev
12: 3195–3205.
34. Qiu H, Mathas M, Nestler S, Bengel C, Nem D, et al. (2010) The unique
complexity of the CYP3A4 upstream region suggests a nongenetic explanation of
its expression variability. Pharmacogenet Genomics 20: 167–178.
35. Arthur JM (2000) The MDCK cell line is made up of populations of cells with
diverse resistive and transport properties. Tissue Cell 32: 446–450.
36. Verkoelen CF, van der Boom BG, Kok DJ, Houtsmuller AB, Visser P, et al.
(1999) Cell type-specific acquired protection from crystal adherence by renal
tubule cells in culture. Kidney Int 55: 1426–1433.
37. Iwano S, Saito T, Takahashi Y, Fujita K, Kamataki T (2001) Cooperative
regulation of CYP3A5 gene transcription by NF-Y and Sp family members.
Biochem Biophys Res Commun 286: 55–60.
Tissue-Specific Expression of CYP3A5 and CYP3A4
PLoS ONE | www.plosone.org 12 January 2012 | Volume 7 | Issue 1 | e3089538. Hashimoto H, Toide K, Kitamura R, Fujita M, Tagawa S, et al. (1993) Gene
structure of CYP3A4, an adult-specific form of cytochrome P450 in human
livers, and its transcriptional control. Eur J Biochem 218: 585–595.
39. Saito T, Takahashi Y, Hashimoto H, Kamataki T (2001) Novel transcriptional
regulation of the human CYP3A7 gene by Sp1 and Sp3 through nuclear factor
kappa B-like element. J Biol Chem 276: 38010–38022.
40. Hyde-DeRuyscher RP, Jennings E, Shenk T (1995) DNA binding sites for the
transcriptional activator/repressor YY1. Nucleic Acids Res 23: 4457–4465.
41. Hariharan N, Kelley DE, Perry RP (1991) Delta, a transcription factor that
binds to downstream elements in several polymerase II promoters, is a
functionally versatile zinc finger protein. Proc Natl Acad Sci U S A 88:
9799–9803.
42. Weill L, Shestakova E, Bonnefoy E (2003) Transcription factor YY1 binds to the
murine beta interferon promoter and regulates its transcriptional capacity with a
dual activator/repressor role. J Virol 77: 2903–2914.
43. Shi Y, Lee JS, Galvin KM (1997) Everything you have ever wanted to know
about Yin Yang 1. Biochim Biophys Acta 1332: F49–66.
44. Cheng X, Klaassen CD (2006) Regulation of mRNA expression of xenobiotic
transporters by the pregnane x receptor in mouse liver, kidney, and intestine.
Drug Metab Dispos 34: 1863–1867.
45. Su AI, Wiltshire T, Batalov S, Lapp H, Ching KA, et al. (2004) A gene atlas of
the mouse and human protein-encoding transcriptomes. Proc Natl Acad
Sci U S A 101: 6062–6067.
46. Masuyama H, Hiramatsu Y, Mizutani Y, Inoshita H, Kudo T (2001) The
expression of pregnane X receptor and its target gene, cytochrome P450 3A1, in
perinatal mouse. Mol Cell Endocrinol 172: 47–56.
47. Novotna A, Doricakova A, Vrzal R, Maurel P, Pavek P, et al. (2010)
Investigation of Orlistat effects on PXR activation and CYP3A4 expression in
primary human hepatocytes and human intestinal LS174T cells. Eur J Pharm
Sci 41: 276–280.
48. Luke MP, Sui G, Liu H, Shi Y (2006) Yin Yang 1 physically interacts with
Hoxa11 and represses Hoxa11-dependent transcription. J Biol Chem 281:
33226–33232.
49. Gordon S, Akopyan G, Garban H, Bonavida B (2006) Transcription factor YY1:
structure, function, and therapeutic implications in cancer biology. Oncogene
25: 1125–1142.
50. Yamakoshi Y, Kishimoto T, Sugimura K, Kawashima H (1999) Human
prostate CYP3A5: identification of a unique 59-untranslated sequence and
characterization of purified recombinant protein. Biochem Biophys Res
Commun 260: 676–681.
51. Henshall J, Galetin A, Harrison A, Houston JB (2008) Comparative analysis of
CYP3A heteroactivation by steroid hormones and flavonoids in different in vitro
systems and potential in vivo implications. Drug Metab Dispos 36: 1332–1340.
52. Lin YS, Dowling AL, Quigley SD, Farin FM, Zhang J, et al. (2002) Co-
regulation of CYP3A4 and CYP3A5 and contribution to hepatic and intestinal
midazolam metabolism. Mol Pharmacol 62: 162–172.
53. Singer GA, Lloyd AT, Huminiecki LB, Wolfe KH (2005) Clusters of co-
expressed genes in mammalian genomes are conserved by natural selection. Mol
Biol Evol 22: 767–775.
54. Greiner B, Eichelbaum M, Fritz P, Kreichgauer HP, von Richter O, et al. (1999)
The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin.
J Clin Invest 104: 147–153.
55. Thompson EE, Kuttab-Boulos H, Witonsky D, Yang L, Roe BA, et al. (2004)
CYP3A variation and the evolution of salt-sensitivity variants. Am J Hum Genet
75: 1059–1069.
56. Tom BH, Rutzky LP, Jakstys MM, Oyasu R, Kaye CI, et al. (1976) Human
colonic adenocarcinoma cells. I. Establishment and description of a new line. In
Vitro 12: 180–191.
57. Cedrone E, Reid Y, Eckard-Amar E (2009) Tissue-culture adapted Influenza
virus strains. ATCC Connection 29: 4–5, 15.
58. Hustert E, Zibat A, Presecan-Siedel E, Eiselt R, Mueller R, et al. (2001) Natural
protein variants of pregnane x receptor with altered transactivation activity
toward cyp3a4. Drug Metab Dispos 29: 1454–1459.
59. Go ¨dtel-Armbrust U, Metzger A, Kroll U, Kelber O, Wojnowski L (2007)
Variability in PXR-mediated induction of CYP3A4 by commercial preparations
and dry extracts of St. John’s wort. Naunyn Schmiedebergs Arch Pharmacol
375: 377–382.
60. Geick A, Eichelbaum M, Burk O (2001) Nuclear receptor response elements
mediate induction of intestinal MDR1 by rifampin. J Biol Chem 276:
14581–14587.
61. Qiu H, Taudien S, Herlyn H, Schmitz J, Zhou Y, et al. (2008) CYP3
phylogenomics: evidence for positive selection of CYP3A4 and CYP3A7.
Pharmacogenet Genomics 18: 53–66.
62. Johnson M, Zaretskaya I, Raytselis Y, Merezhuk Y, McGinnis S, et al. (2008)
NCBI BLAST: a better web interface. Nucleic Acids Res 36: W5–9.
63. Brudno M, Do CB, Cooper GM, Kim MF, Davydov E, et al. (2003) LAGAN
and Multi-LAGAN: efficient tools for large-scale multiple alignment of genomic
DNA. Genome Res 13: 721–731.
64. Hall TA (1999) BioEdit: a user-friendly biological sequence alignment editor and
analysis program for Windows 95/98/NT. Nucl Acids Symp Ser 41: 95–98.
65. Chekmenev DS, Haid C, Kel AE (2005) P-Match: transcription factor binding
site search by combining patterns and weight matrices. Nucleic Acids Res 33:
W432–437.
66. Gellner K, Eiselt R, Hustert E, Arnold H, Koch I, et al. (2001) Genomic
organization of the human CYP3A locus: identification of a new, inducible
CYP3A gene. Pharmacogenetics 11: 111–121.
67. Tegude H, Schnabel A, Zanger UM, Klein K, Eichelbaum M, et al. (2007)
Molecular mechanism of basal CYP3A4 regulation by hepatocyte nuclear factor
4alpha: evidence for direct regulation in the intestine. Drug Metab Dispos 35:
946–954.
68. Qiu H (2008) Comparative genomics and phylogenetics of the vertebrate CYP3
family. Dissertation am Fachbereich Biologie der Johannes Gutenberg-
Universita ¨t Mainz.
Tissue-Specific Expression of CYP3A5 and CYP3A4
PLoS ONE | www.plosone.org 13 January 2012 | Volume 7 | Issue 1 | e30895